Transdermal estradiol therapy for advanced prostate cancer - Forward to the past?

Journal of Urology

Volumn 169, Issue 5, 2003, Pages 1735-1737

  Ockrim, J L ^a   Lalani, E N ^a   Laniado, M E ^a   Carter, S St C ^a   Abel, P D ^a  

^a NONE

Author keywords

Administration, cutaneous; Prostatic neoplasms, estrogens

Indexed keywords

ESTRADIOL; ESTROGEN; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADVANCED CANCER; ARTICLE; BLOOD FLOW; BONE DENSITY; BONE MINERAL; CANCER HORMONE THERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG TOLERABILITY; FIRST PASS EFFECT; FOLLOW UP; GYNECOMASTIA; HEART PROTECTION; HOT FLUSH; HUMAN; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 0037405518     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000061024.75334.40     Document Type: Article

References (15)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T. and Thun, M.: Cancer statistics, 2001. CA Cancer J Clin, 51: 15, 2001
2. Aro, J.: Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population. Prostate, 18: 131, 1991
3. Hedlund, P. O. and Henriksson, P.: Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study. Urology, 55: 328, 2000
4. van Kesteren, P. J., Asscheman, H., Megens, J. A. and Gooren, L. J.: Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol, 47: 337, 1997
5. Mikkola, A. K., Ruutu, M. L., Aro, J. L., Rannikko, S. A. and Salo, J. O.: Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group. Br J Urol, 82: 63, 1998
6. Mijatovic, V. and Pines, A.: The first clinical synthesis conference on hormone replacement therapy: new perspectives for HRT? Maturitas, 33: 87, 1999
7. Carlstrom, K., Collste, L., Eriksson, A., Henriksson, P., Pousette, A., Stege, R. et al: A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy. Prostate, 14: 177, 1989
8. von Schoultz, B., Carlstrom, K., Collste, L., Eriksson, A., Henriksson, P., Pousette, A. et al: Estrogen therapy and liver function - metabolic effects of oral and parenteral administration. Prostate, 14: 389, 1989
9. Henriksson, P., Blomback, M., Eriksson, A., Stege, R. and Carlstrom, K.: Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol, 65: 282, 1990
10. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B. et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 280: 605, 1998
11. Ferro, M. A.: Use of intravenous stilbestrol diphosphate in patients with prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin North Am, 18: 139, 1991
12. Spetz, A.-C., Hammar, M., Lindberg, B., Spångberg, A., Varenhorst, E. and the Scandinavian Prostatic Cancer Group - 5 Trial Study: Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol, 166: 517, 2001
13. Daniell, H. W., Dunn, S. R., Ferguson, D. W., Lomas, G., Niazi, Z. and Stratte, P. T.: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol, 163: 181, 2000
14. Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A. et al: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med, 345: 948, 2001
15. Walsh, P. C., DeWeese, T. L. and Eisenberger, M. A.: A structured debate: immediate versus deferred androgen suppression in prostate cancer - evidence for deferred treatment. J Urol, 166: 508, 2001